<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35178313</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2168-8184</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>14</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Cureus</Title>
          <ISOAbbreviation>Cureus</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Management of Attention Deficits and Behavioral Dyscontrol With an Evening-Dosed Methylphenidate Formulation in Smith-Magenis Syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>e21255</StartPage>
          <MedlinePgn>e21255</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e21255</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.21255</ELocationID>
        <Abstract>
          <AbstractText>Smith-Magenis syndrome (SMS) is a severe neurodevelopmental disorder characterized by intellectual disability, sleep abnormalities, behavioral dyscontrol, and a distinct somatic phenotype. This report describes the case of a 10-year-old female with SMS who presented with aggression, self-injurious behavior, impulsivity, and attention deficits. She had failed trials of several stimulants and clonidine prior to presentation. An evening-dosed, delayed-release/extended-release methylphenidate formulation was added to her regimen, and she demonstrated significant improvement in her presenting symptoms. To our knowledge, this is the first published case of the use of an evening-dosed, delayed-release/extended-release methylphenidate formulation in a patient with SMS. This case highlights the need for further research on the role of these medications in managing behavioral and attentional symptoms associated with SMS.</AbstractText>
          <CopyrightInformation>Copyright © 2022, Narlesky et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Narlesky</LastName>
            <ForeName>Matthew R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatry, Unity Health, Searcy, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McDonald</LastName>
            <ForeName>Devin</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatry, Unity Health, Searcy, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bradford</LastName>
            <ForeName>Brian</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Child and Adolescent Psychiatry, University of Utah School of Medicine, Salt Lake City, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sukpraprut-Braaten</LastName>
            <ForeName>Suporn</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Research, Unity Health, Searcy, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Strayhan</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatry, Unity Health, Searcy, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cureus</MedlineTA>
        <NlmUniqueID>101596737</NlmUniqueID>
        <ISSNLinking>2168-8184</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">17p11.2 deletion</Keyword>
        <Keyword MajorTopicYN="N">behavioral dyscontrol</Keyword>
        <Keyword MajorTopicYN="N">impulsivity</Keyword>
        <Keyword MajorTopicYN="N">inverted circadian rhythm</Keyword>
        <Keyword MajorTopicYN="N">jornay</Keyword>
        <Keyword MajorTopicYN="N">melatonin agonist</Keyword>
        <Keyword MajorTopicYN="N">methylphenidate</Keyword>
        <Keyword MajorTopicYN="N">microdeletion</Keyword>
        <Keyword MajorTopicYN="N">smith-magenis syndrome</Keyword>
        <Keyword MajorTopicYN="N">sms</Keyword>
      </KeywordList>
      <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35178313</ArticleId>
        <ArticleId IdType="pmc">PMC8841495</ArticleId>
        <ArticleId IdType="doi">10.7759/cureus.21255</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Smith ACM, Finucane B. Philadelphia, PA: Lippincott Williams &amp; Wilkins;  [
Nov;
2021 
]. 2017. Smith-Magenis syndrome; pp. 254–255.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith ACM, Boyd KE, Brennan C, et al.  In GeneReviews [Internet] Seattle, WA: University of Washington; 2001. Smith-Magenis syndrome.</Citation>
        </Reference>
        <Reference>
          <Citation>Interstitial deletion of (17)(p11.2p11.2) in nine patients. Smith AC, McGavran L, Robinson J, et al.  Am J Med Genet. 1986;24:393–414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2425619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Refinement of the Smith-Magenis syndrome critical region to ∼950KB and assessment of 17P11.2 deletions. Are all deletions created equally? Vlangos CN, Yim DK, Elsea SH. Mol Genet Metab. 2003;79:134–141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12809645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith-Magenis syndrome. Elsea SH, Girirajan S. Eur J Hum Genet. 2008;16:412–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18231123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RAI1 variations in Smith-Magenis syndrome patients without 17p11.2 deletions. Girirajan S, Elsas LJ II, Devriendt K, Elsea SH. J Med Genet. 2005;42:820–828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1735950</ArticleId>
            <ArticleId IdType="pubmed">15788730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molecular analysis of the Smith-Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2) Greenberg F, Guzzetta V, Montes de Oca-Luna R, et al.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1686451/ Am J Hum Genet. 1991;49:1207–1218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1686451</ArticleId>
            <ArticleId IdType="pubmed">1746552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Greenberg F, Lewis RA, Potocki L, et al.  Am J Med Genet. 1996;62:247–254.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8882782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome. Laje G, Bernert R, Morse R, Pao M, Smith AC. Am J Med Genet C Semin Med Genet. 2010;154C:463–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3022344</ArticleId>
            <ArticleId IdType="pubmed">20981776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>β1-adrenergic antagonists and melatonin reset the clock and restore sleep in a circadian disorder, Smith-Magenis syndrome. De Leersnyder H, Bresson JL, de Blois MC, et al.  J Med Genet. 2003;40:74–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1735264</ArticleId>
            <ArticleId IdType="pubmed">12525548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durham, NC: Ironshore Pharmaceuticals; 2019. JORNAY PM [package insert]</Citation>
        </Reference>
        <Reference>
          <Citation>Pharmacokinetics of HLD200, a delayed-release and extended-release methylphenidate: evaluation of dose proportionality, food effect, multiple-dose modeling, and comparative bioavailability with immediate-release methylphenidate in healthy adults. Liu T, Gobburu JV, Po MD, McLean A, DeSousa NJ, Sallee FR, Incledon B. J Child Adolesc Psychopharmacol. 2019;29:181–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6479242</ArticleId>
            <ArticleId IdType="pubmed">30810347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2) Gropman AL, Duncan WC, Smith AC. Pediatr Neurol. 2006;34:337–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16647992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behavioral disturbance and treatment strategies in Smith-Magenis syndrome. Poisson A, Nicolas A, Cochat P, et al.  Orphanet J Rare Dis. 2015;10:111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4559928</ArticleId>
            <ArticleId IdType="pubmed">26336863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abnormal general movements in girls with Rett disorder: the first four months of life. Einspieler C, Kerr AM, Prechtl HF. Brain Dev. 2005;27:0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16182501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Methodological note: video analysis of the early development of Rett syndrome—one method for many disciplines. Marschik PB, Einspieler C. Dev Neurorehabil. 2011;14:355–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22136120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Case of Smith-Magenis syndrome. Khan SS, Pradhan T. J Clin Psychopharmacol. 2019;39:525–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31433341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Leersnyder H. In Handbook of Clinical Neurology. Vol. 111. Elsevier; 2013. Chapter 34 - Smith-Magenis syndrome; pp. 295–296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23622179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adrenocorticotropic hormone therapy improved spasms and sleep disturbance in Smith-Magenis syndrome: a case report. Momosaki K, Kido J, Matsumoto S, Ozasa S, Nakamura K. Pediatr Rep. 2020;24:72–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7717653</ArticleId>
            <ArticleId IdType="pubmed">33114276</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
